Announced Date: 2025-06-02 (June 2, 2025)
Asset Name: BNT327 (PM8002 from Biotheus)
Licensor: Biopharmaceutical New Technologies (BioNTech)
Licensee (Buyer): Bristol Myers Squibb (BMS)
.
Asset Modality: BsAbs (bispecific antibody)
Asset Target: targeting PD-L1 and VEGF-A
Potential Indication: numerous solid tumor types
Current Stage: global Phase 3 trials, first-line treatment in extensive stage small cell lung cancer (“ES-SCLC”) and non-small cell lung cancer (“NSCLC”)
.
Scope of Authority:
BioNTech and BMS will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products.
Both companies have the right to independently develop BNT327 in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets.
.
Payment Detail:
BioNTech will be eligible to receive:
Upfront payment of $1.5 billion,
$2 billion total in non-contingent anniversary payments through 2028,
Development, regulatory and commercial milestone payments up to $7.6 billion.
Milestone payments up to $4.8 billion
Total up to $11.1 billion.
.
BioNTech and BMS will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions. Global profits/losses will be equally shared between BioNTech and BMS.
Link:
